More recently, Punnoose et al. evaluated the possibility to detect EGFR mutations in CTCs of NSCLC patients using the same approach for CTC preparation and a real-time quantitative TaqMan assay [24]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.